Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2399-2412

  Chen, Li ^a,b   Zhou, Xia ^a   Fan, Lucy X ^a   Yao, Ying ^a   Swenson Fields, Katherine I ^a,c   Gadjeva, Mihaela ^d   Wallace, Darren P ^a   Peters, Dorien J M ^e   Yu, Alan ^a   Grantham, Jared J ^a   Li, Xiaogang ^a,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYCYSTIN 1; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR ALPHA; CCL2 PROTEIN, HUMAN; CCL2 PROTEIN, MOUSE; ISOMERASE; MIF PROTEIN, HUMAN; MIF PROTEIN, MOUSE; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEEDBACK SYSTEM; FEMALE; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL LINE; DISEASE MODEL; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; CELL LINE; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930399294     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80467     Document Type: Article

References (56)

1. Harris PC. Autosomal dominant polycystic kidney disease: Clues to pathogenesis. Hum Mol Genet. 1999;8(10): 1861-1866.
2. Zhou X, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Invest. 2013;123(7): 3084-3098.
3. Fan LX, Li X, Magenheimer B, Calvet JP, Li X. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 2012;81(1): 76-85.
4. Fan LX, et al. Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts. J Am Soc Nephrol. 2013;24(12): 2010-2022.
5. Swenson-Fields KI, et al. Macrophages promote polycystic kidney disease progression. Kidney Int. 2013;83(5): 855-864.
6. Karihaloo A, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2011;22(10): 1809-1814.
7. Lolis E, Bucala R. Macrophage migration inhibitory factor. Expert Opin Ther Targets. 2003;7(2): 153-164.
8. Calandra T, Roger T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol. 2003;3(10): 791-800.
9. Bacher M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A. 1996;93(15): 7849-7854.
10. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994;179(6): 1895-1902.
11. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine. 1998;10(3): 199-205.
12. Imamura K, et al. Identification and immunohistochemical localization of macrophage migration inhibitory factor in human kidney. Biochem Mol Biol Int. 1996;40(6): 1233-1242.
13. Chen Z, et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24(4): 709-714.
14. Kasama T, Ohtsuka K, Sato M, Takahashi R, Wakabayashi K, Kobayashi K. Macrophage migration inhibitory factor: A multifunctional cytokine in rheumatic diseases. Arthritis. 2010;2010: 106202.
15. Morimoto T, Nishihira J, Kohgo T. Immunohistochemical localization of macrophage migration inhibitory factor (MIF) in human gingival tissue and its pathophysiological functions. Histochem Cell Biol. 2003;120(4): 293-298.
16. Lan HY. Role of macrophage migration inhibition factor in kidney disease. Nephron Exp Nephrol. 2008;109(3): E79-e83.
17. Matsumoto K, Kanmatsuse K. Increased production of macrophage migration inhibitory factor by T cells in patients with IgA nephropathy. Am J Nephrol. 2001;21(6): 455-464.
18. Lan HY, et al. TNF-Alpha up-regulates renal MIF expression in rat crescentic glomerulonephritis. Mol Med. 1997;3(2): 136-144.
19. Hoi AY, et al. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/ lpr mice. J Immunol. 2006;177(8): 5687-5696.
20. Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-Activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999;274(25): 18100-18106.
21. Lue H, et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2006;18(5): 688-703.
22. Miller EJ, et al. Macrophage migration inhibitory factor stimulates AMP-Activated protein kinase in the ischaemic heart. Nature. 2008;451(7178): 578-582.
23. Brock SE, Rendon BE, Yaddanapudi K, Mitchell RA. Negative regulation of AMP-Activated protein kinase (AMPK) activity by macrophage migration inhibitory factor (MIF) family members in non-small cell lung carcinomas. J Biol Chem. 2012;287(45): 37917-37925.
24. Fingerle-Rowson G, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A. 2003;100(16): 9354-9359.
25. Toh ML, et al. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol. 2006;177(7): 4818-4825.
26. Gregory JL, et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol. 2006;177(11): 8072-8079.
27. Lue H, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007;26(35): 5046-5059.
28. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell. 2005;17(2): 225-236.
29. Takiar V, et al. Activating AMP-Activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011;108(6): 2462-2467.
30. Shillingford JM, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006;103(14): 5466-5471.
31. Shillingford JM, Leamon CP, Vlahov IR, Weimbs T. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol. 2012;23(10): 1674-1681.
32. Li X, et al. A tumor necrosis factor-Alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med. 2008;14(8): 863-868.
33. Rowe I, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013;19(4): 488-493.
34. Zheng D, et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003;14(10): 2588-2595.
35. Shibazaki S, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet. 2008;17(11): 1505-1516.
36. Al-Abed Y, VanPatten S. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem. 2011;3(1): 45-63.
37. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol. 2008;19(9): 1659-1662.
38. Lantinga-van Leeuwen IS, et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet. 2004;13(24): 3069-3077.
39. Cowley BD, Cowley BD Jr, Ricardo SD, Nagao S, Diamond JR. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats. Kidney Int. 2001;60(6): 2087-2096.
40. Benigni F, et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest. 2000;106(10): 1291-1300.
41. Sanchez-Nino MD, et al. MIF, CD74 and other partners in kidney disease: Tales of a promiscuous couple. Cytokine Growth Factor Rev. 2013;24(1): 23-40.
42. Bernhagen J, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5): 587-596.
43. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10): 556-566.
44. Seeger-Nukpezah T, et al. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A. 2013;110(31): 12786-12791.
45. Schulz R, et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012;209(2): 275-289.
46. Rees AJ. Monocyte and macrophage biology: An overview. Semin Nephrol. 2010;30(3): 216-233.
47. Warburg O. On the origin of cancer cells. Science. 1956;123(3191): 309-314.
48. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324(5930): 1029-1033.
49. Leng L, et al. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003;197(11): 1467-1476.
50. Sweeney WE, Sweeney WE Jr, von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008;19(7): 1331-1341.
51. Mitchell RA, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002;99(1): 345-350.
52. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190(10): 1375-1382.
53. Li X, Luo Y, Starremans PG, McNamara CA, Pei Y, Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol. 2005;7(12): 1202-1212.
54. Wei F, et al. Neutrophil gelatinase-Associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney Int. 2008;74(10): 1310-1318.
55. Shao X, Somlo S, Igarashi P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol. 2002;13(7): 1837-1846.
56. Gadjeva M, Nagashima J, Zaidi T, Mitchell RA, Pier GB. Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog. 2010;6(3): E1000826.